Macitentan Stada 10 mg film-coated tablets EFG
Macitentan contains the active substance macitentan, which belongs to a class of medicines called “endothelin receptor antagonists”.
Macitentan is used for the long-term treatment of pulmonary arterial hypertension (PAH):
It can be used alone or with other medicines for PAH. PAH is high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary arteries). In people with PAH, these arteries can become narrowed, so the heart has to work harder to pump blood through them. As a result, those affected feel tired, dizzy, and have difficulty breathing.
Macitentan widens the pulmonary arteries, making it easier for the heart to pump blood through them. This reduces blood pressure, alleviates symptoms, and improves the progression of the disease.
If you meet any of the above points, inform your doctor.
Consult your doctor or pharmacist before starting to take macitentan.
You will need to have blood tests, as indicated by your doctor:
Your doctor will perform blood tests before you start treatment with macitentan and during treatment to determine:
If you have anemia (reduced number of red blood cells), you may have the following signs:
If you experience any of these signs, talk to your doctor.
Signs that your liver may not be working properly are:
If you experience any of these signs, inform your doctor immediately.
If you have kidney problems, talk to your doctor before using macitentan. Macitentan may cause a greater reduction in blood pressure and a decrease in hemoglobin in patients with kidney problems.
The use of medicines for the treatment of PAH, including macitentan, in patients with pulmonary veno-occlusive disease (obstruction of the pulmonary veins) may cause pulmonary edema. If you experience signs of pulmonary edema during treatment with macitentan, such as a sudden and significant increase in shortness of breath and oxygen, talk to your doctor immediately.Your doctor may perform additional tests and determine the most suitable treatment for you.
Do not give this medicine to children under 2 years of age because the efficacy and safety have not been established.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Macitentan may affect other medicines.
If you take macitentan with other medicines, including those listed below, the effects of macitentan or other medicines may be affected. Talk to your doctor or pharmacist if you are taking any of the following medicines:
If you take piperine as a dietary supplement, it may alter the way your body responds to some medicines like macitentan. Talk to your doctor or pharmacist if this is the case.
If you are pregnant or breast-feeding, or think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Macitentan may harm fetuses conceived before, during, or shortly after treatment.
If you are a woman of childbearing age, your doctor will ask you to have a pregnancy test before starting to take macitentan and periodically (once a month) during treatment.
It is not known if macitentan passes into breast milk. Do not breast-feed during treatment with macitentan. Talk to your doctor about this.
If you are a man taking macitentan, this medicine may decrease your sperm count. Talk to your doctor if you have any questions or concerns about this.
Macitentan may cause side effects such as headaches and hypotension (indicated in section 4) and the symptoms of the disease can also make you less fit to drive or use machines.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Macitentan should only be prescribed by a doctor with experience in the treatment of pulmonary arterial hypertension.
Follow exactly the instructions of administration indicated by your doctor. If you are unsure, consult your doctor again.
Adults and children under 18 years of age with a minimum weight of 40 kg
The recommended dose of macitentan is one 10 mg tablet once a day. Swallow the tablet whole, with a glass of water, and do not chew or break it. Macitentan can be taken with or without food. It is best to take the tablet at the same time each day.
For children who weigh less than 40 kg, other brands of macitentan are available in dispersible tablets with a lower dose.
If you take more tablets than indicated, you may experience headache, nausea, or vomiting. Seek advice from your doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take macitentan, take a dose as soon as you remember and, from then on, continue to take the tablets at the usual times. Do not take a double dose to make up for forgotten doses.
Macitentan is a treatment that you should continue to take to control PAH. Do not stop taking macitentan unless you have agreed this with your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects, uncommon(may affect up to 1 in 100 people)
If you experience any of these signs, talk to your doctor immediately.
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
The side effects listed above can also be observed in children. Other very common side effects in children are upper respiratory tract infections (infection of the nose, sinuses, or throat) and gastroenteritis (inflammation of the stomach and intestine). Rhinitis (itching, discharge, or blockage of the nose) was also commonly observed in children.
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Monitoring System: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Macitentan after the expiry date which is stated on the carton and blister after “EXP”. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. This will help to protect the environment.
The active substance is macitentan. Each film-coated tablet contains 10 mg of macitentan.
The other ingredients are maltodextrin (E1400), polysorbate 80 (E433), mannitol (E421), pregelatinized starch (from corn), sodium croscarmellose (E468), magnesium stearate (E572), poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171), glycerol monocaprylocaprate, type I, sodium lauryl sulfate (E487).
Macitentan Stada is presented as film-coated tablets.
White to off-white, round, biconvex film-coated tablets, approximately 5.6 mm in diameter.
Macitentan Stada 10 mg is available in PVC/PE/PVdC-Al blisters containing 15 or 30 film-coated tablets or unit-dose blisters of PVC/PE/PVdC-Al containing 15x1 or 30x1 film-coated tablets.
Not all pack sizes may be marketed.
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
info@stada.es
Manufacturer
Stada Arzneimittel AGStadastrase 2-1861118 Bad VilbelGermany
or
Clonmel Healthcare Ltd.
Waterford Road, Clonmel
E91 D768 Co. Tipperary
Ireland
or
Stada Arzneimittel GmbHMuthgasse 36/21190 ViennaAustria
or
Centrafarm Services B.V.Van de Reijtstraat 31 E4814 NE BredaNetherlands
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)